Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04925193 |
Recruitment Status :
Recruiting
First Posted : June 14, 2021
Last Update Posted : February 5, 2024
|
Sponsor:
University of Colorado, Denver
Collaborators:
Karyopharm Therapeutics Inc
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Colorado, Denver
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | November 2024 |
Estimated Study Completion Date : | November 2025 |